THERANEXUS news, videos and press releases - Page 4
For more news please use our advanced search feature.
THERANEXUS - More news...
THERANEXUS - More news...
- THERANEXUS PLANS TO EXPAND ITS PHASE II PIPELINE WITH A THIRD PROGRAM
- THERANEXUS ANNOUNCES THAT RODOLPHE BESSERVE WILL JOIN ITS BOARD OF DIRECTORS
- THERANEXUS ANNOUNCES A NEW EUROPEAN PATENT PROTECTING THN201, ITS DRUG CANDIDATE FOR THE TREATMENT OF NEUROCOGNITIVE DISORDERS INCLUDING THOSE ASSOCIATED WITH ALZHEIMERS
- RECOGNITION OF THE SCIENTIFIC EXCELLENCE OF THERANEXUS
- THERANEXUS ANNOUNCES ITS FIRST HALF 2018 RESULTS - CASH POSITION AT JUNE 30, 2018: EUR 14.9 million
- THERANEXUS OBTAINS THE AUTHORIZATION TO START A PHASE Ib CLINICAL TRIAL WITH ITS DRUG CANDIDATE THN201 IN NEUROCOGNITIVE DISORDERS DUE TO ALZHEIMER'S DISEASE
- THERANEXUS ANNOUNCES THE INCLUSION OF THE FIRST PATIENT IN ITS PHASE 2 CLINICAL TRIAL EVALUATING ITS DRUG CANDIDATE THN102 IN EXCESSIVE DAYTIME SLEEPINESS (EDS) IN PATIENTS WITH PARKINSON'S DISEASE
- THERANEXUS PRESENTS NEW DATE ON THE STIMULATING EFFECT OF ITS DRUG CANDIDATE THN102
- THERANEXUS ANNOUNCES GERMAN AUTHORITIES APPROVAL FOR ITS PHASE 2 CLINICAL TRIAL IN PARKINSON'S DISEASE
- THERANEXUS ANNOUNCES THE PUBLICATION OF A SCIENTIFIC ARTICLE ON THE MECHANISM OF ACTION OF DRUG CANDIDATE THN102 IN THE INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- THERANEXUS PUBLISHES ITS CASH POSITION AS AT 31 MARCH 2018
- Theranexus presentation at the International Connexins Symposium (Vancouver 14-15 May 2018)
- ORAL PRESENTATION OF THERANEXUS AT THE 9TH EUROPEAN CONGRESS ON NARCOLEPSY 5 AND 6 MAY IN MONTPELLIER
- THERANEXUS ANNOUNCES ITS 2017 ANNUAL RESULTS AND PRESENTS AN UPDATE ON THE PROGRESS OF ITS CLINICAL TRIALS
- THN102 OBTAINS INVESTIGATIONAL NEW DRUG STATUS FROM THE FOOD AND DRUG ADMINISTRATION (FDA)
- THERANEXUS ANNOUNCES THE FIRST EUROPEAN APPROVAL FOR ITS PHASE 2 CLINICAL TRIAL WITH THN 102 IN PARKINSON'S DISEASE PATIENTS
- THERANEXUS ANNOUNCES A SUCCESSFUL CLINICAL PHARMACOKINETIC STUDY AS PART OF THE DEVELOPMENT OF ITS DRUG CANDIDATES THN201 AND THN101
- THERANEXUS AND THE COLLEGE DE FRANCE SIGN A RESEARCH AGREEMENT ON ASTROCYTE-NEURON INTERACTIONS
- THERANEXUS ANNOUNCES ISSUANCE OF EUROPEAN PATENT COVERING ITS DRUG CANDIDATE THN102 FOR TREATMENT OF NARCOLEPSY AND PARKINSON'S DISEASE